Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in France, Italy, Spain, and Germany
Author(s)
Pavo Marijic, MSc1, Ginita Jutlla, MSc2, Thierry Schaffner, PhD3, Elise Kuylen, PhD4, Gaurav Mathur, MSc5, Nicola Clarke, MSc6, Andrew Easton, MSc6, Christian Rauschert, PhD7, Stefano Castagna, MSc8, Simona Comparoni, MSc8, Celine Pribil, MSc9, Laure-Anne Cussac, MSc10, Laura Amanda Vallejo-Aparicio, MSc11, Carmen Gonzalez, MSc11, Thatiana de Jesus Pereira Pinto, PhD4, Zeki Kocaata, PhD4.
1Manager Market Access, GSK, München, Germany, 2GSK, London, United Kingdom, 3GSK, Baar, Switzerland, 4GSK, Wavre, Belgium, 5GSK, Philadelphia, PA, USA, 6Health Economics & Outcomes Research Ltd, Cardiff, United Kingdom, 7GSK, Munich, Germany, 8GSK, Verona, Italy, 9Laboratoire GSK, Rueil Malmaison, France, 10GSK, Rueil Malmaison, France, 11GSK, Madrid, Spain.
1Manager Market Access, GSK, München, Germany, 2GSK, London, United Kingdom, 3GSK, Baar, Switzerland, 4GSK, Wavre, Belgium, 5GSK, Philadelphia, PA, USA, 6Health Economics & Outcomes Research Ltd, Cardiff, United Kingdom, 7GSK, Munich, Germany, 8GSK, Verona, Italy, 9Laboratoire GSK, Rueil Malmaison, France, 10GSK, Rueil Malmaison, France, 11GSK, Madrid, Spain.
OBJECTIVES: To perform a systematic literature review to quantify the epidemiology and extent of the disease burden, complications, and economic burden of invasive meningococcal disease (IMD) in France, Italy, Spain, and Germany, focusing on adolescents and young adults (10-24-year-olds).
METHODS: Searches in March 2025 included peer-reviewed literature from MEDLINE and Embase (past 10 years), conference proceedings (past 3 years), and relevant websites and governmental/non-governmental organizations. Outcomes included epidemiological and disease burden and acute and long-term healthcare resource utilization and costs.
RESULTS: Data for France, Italy, Spain, and Germany were extracted from 35, 31, 28, and 9 sources, respectively. IMD incidence decreased over time. European Centre for Disease Prevention and Control 2023 notification data show that IMD incidence was highest among <5-year-olds, followed by 15-24-year-olds. Meningococcal serogroup B (MenB) was the most prevalent serogroup across countries and years. MenB incidence rates per 100,000 individuals in 2023 among 10-24-year-olds were highest in 18-year-olds in France (1.57), 16-17-year-olds in Germany (0.25-0.26), 15-19-year-olds in Spain (0.53), and 15-24-year-olds in Italy (0.22) (age groupings varied by country). For 10-24-year-olds, IMD resulted in sequelae in 10-26% (mainly epilepsy and anxiety) and death in 0-25%. In 10-24-year-olds, acute hospitalization duration averaged 8-13 days, costing approximately €5,000-26,000; long-term sequelae and indirect costs were reported to be €41,000-52,000 and €300-1,600, respectively.
CONCLUSIONS: Although IMD incidence has decreased with the introduction of vaccination programs, there remains a second peak among adolescents and young adults, in whom serogroup B remains dominant. Individuals who contract IMD are at risk of severe complications and high acute and long-term costs. These findings highlight the current status of IMD in Europe, underscore the importance of prevention, and can be used to help inform health strategies and economic planning for better disease prevention and management.
METHODS: Searches in March 2025 included peer-reviewed literature from MEDLINE and Embase (past 10 years), conference proceedings (past 3 years), and relevant websites and governmental/non-governmental organizations. Outcomes included epidemiological and disease burden and acute and long-term healthcare resource utilization and costs.
RESULTS: Data for France, Italy, Spain, and Germany were extracted from 35, 31, 28, and 9 sources, respectively. IMD incidence decreased over time. European Centre for Disease Prevention and Control 2023 notification data show that IMD incidence was highest among <5-year-olds, followed by 15-24-year-olds. Meningococcal serogroup B (MenB) was the most prevalent serogroup across countries and years. MenB incidence rates per 100,000 individuals in 2023 among 10-24-year-olds were highest in 18-year-olds in France (1.57), 16-17-year-olds in Germany (0.25-0.26), 15-19-year-olds in Spain (0.53), and 15-24-year-olds in Italy (0.22) (age groupings varied by country). For 10-24-year-olds, IMD resulted in sequelae in 10-26% (mainly epilepsy and anxiety) and death in 0-25%. In 10-24-year-olds, acute hospitalization duration averaged 8-13 days, costing approximately €5,000-26,000; long-term sequelae and indirect costs were reported to be €41,000-52,000 and €300-1,600, respectively.
CONCLUSIONS: Although IMD incidence has decreased with the introduction of vaccination programs, there remains a second peak among adolescents and young adults, in whom serogroup B remains dominant. Individuals who contract IMD are at risk of severe complications and high acute and long-term costs. These findings highlight the current status of IMD in Europe, underscore the importance of prevention, and can be used to help inform health strategies and economic planning for better disease prevention and management.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
SA88
Topic
Study Approaches
Disease
Rare & Orphan Diseases, Vaccines